KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
An Online Treatment Decision Aid for Men with Low-risk Prostate Cancer Eligible for Active Surveillance and Their Partners Increases the Uptake of Active Surveillance: The Navigate Randomised Controlled Trial. PMID 40222891 · Eur Urol Oncol · 2025-Oct The study is a randomized controlled trial in low-risk prostate cancer, but it evaluates a decision aid (non-drug intervention) and its primary endpoint is uptake of active surveillance (a categorical treatment choice), not a time-to-event efficacy endpoint like OS, PFS, or DFS. No Kaplan-Meier or hazard ratio results are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials. PMID 40147791 · J Hepatol · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness comparison between ceftazidime-avibactam and carbapenem-based regimens in nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections. PMID 40059019 · J Microbiol Immunol Infect · 2025-Oct The study is a retrospective, observational, single-center study in infectious diseases (nosocomial bacteremia), not an oncology randomized controlled trial. It does not meet the required oncology, randomized, or Phase III criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Undisclosed Conflicts of Interest in Japanese Cancer Clinical Trials: A Cross-Sectional Study of Author-Pharmaceutical Industry Financial Relationships. PMID 40030121 · JCO Oncol Pract · 2025-Oct The record is a cross-sectional study analyzing conflicts of interest in Japanese cancer clinical trials. While it references Phase III randomized trials, the study itself is not an original report of a trial's efficacy results. It lacks any time-to-event efficacy endpoint and does not present drug intervention outcomes from a specific trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endoscopic suturing to prevent migration of esophageal fully covered self-expandable metal stents: a randomized controlled trial (with video). PMID 40024292 · Gastrointest Endosc · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Physical recovery after local resection of nonpedunculated rectal adenomas and T1 carcinomas: endoscopic submucosal dissection versus transanal minimally invasive surgery. PMID 39956469 · Gastrointest Endosc · 2025-Oct The study is excluded because it is not a drug intervention trial and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier analysis or hazard ratio. The primary endpoint is mean time to recovery, a functional outcome, not a survival endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized comparison of precut papillotomy versus an endoscopic ultrasound-guided rendezvous procedure for difficult biliary access in malignant distal biliary obstruction. PMID 39799946 · Endoscopy · 2025-Oct The study is a randomized controlled trial in an oncology context, but it compares two procedural techniques (endoscopic interventions) and does not involve a drug-containing intervention. The primary and secondary outcomes are technical success, adverse events, procedure duration, and length of stay, which are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05). PMID 39727010 · Cancer Res Treat · 2025-Oct The record describes a randomized Phase III trial (PREMIER, KCSG GU16-05) evaluating pemetrexed maintenance vs. observation in advanced urothelial carcinoma, with PFS as primary and OS as secondary time-to-event endpoints, reporting HRs and KM data. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 1 Figure · 2 Panel · risk not_visible
CAMONCO 2: Results From a Randomized Controlled Trial Comparing Open Dialogue About Complementary Alternative Medicine and Standard Care on Patients' Quality of Life. PMID 39700437 · JCO Oncol Pract · 2025-Oct The trial is randomized and oncology-focused with a time-to-event endpoint (overall survival), but it lacks explicit confirmation of Phase III/IIIb or Phase II/III, and the intervention (Open Dialogue About Complementary Alternative Medicine) is not a pharmacologic drug intervention, which is required for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The effect of lobar versus sublobar video-assisted thoracoscopic surgery lung resection on patient quality of life. PMID 41376921 · J Thorac Dis · 2025-Nov-30 Study is a non-randomized, retrospective analysis of surgical procedures (lobectomy vs. sublobar resection) for lung cancer with a primary quality-of-life endpoint, not a randomized drug trial with a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Role of fallopian tube and cervical canal occlusion in preventing intra-operative tumour spillage in early endometrial cancer- a pilot study. PMID 41318519 · World J Surg Oncol · 2025-Nov-29 The study is a pilot randomized trial of a surgical technique (cervical/tubal occlusion) to prevent tumor spillage in endometrial cancer, without a drug intervention, and does not report a time-to-event efficacy endpoint. It is not a Phase III or definitive randomized trial of a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of lidocaine versus sufentanil in patient-controlled intravenous analgesia after laparoscopic colorectal cancer surgery: a prospective, randomized, double-blind clinical trial. PMID 41318377 · BMC Anesthesiol · 2025-Nov-29 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Is there a difference in the postoperative quality of recovery and analgesia between erector spinae and serratus anterior plane blocks following modified radical mastectomy: a randomized controlled study. PMID 41315952 · BMC Anesthesiol · 2025-Nov-29 The study is a randomized controlled trial in oncology patients but compares two regional anesthesia techniques (erector spinae plane block vs. serratus anterior plane block) for postoperative analgesia and recovery quality. It is not a Phase III/IIIb or Phase II/III trial of a systemic drug intervention. The primary endpoint is a patient-reported quality of recovery score (QoR-40), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR is reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer. PMID 41316390 · Breast Cancer Res · 2025-Nov-28 The record describes a non-randomized, single-arm, Phase 1b/2 trial. The primary efficacy endpoint is pathological complete response (pCR), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for a randomized trial with a time-to-event primary/key secondary endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer. PMID 41316032 · BMC Cancer · 2025-Nov-28 The record is a Phase 4 observational, retrospective, non-randomized study. It does not meet the inclusion criteria for an original formal result of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors. PMID 41315323 · Sci Rep · 2025-Nov-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial. PMID 41315271 · Nat Commun · 2025-Nov-28 The report is a randomized, oncology trial with drug intervention and time-to-event efficacy (EFS), but it is explicitly described as a 'pilot trial' and lacks evidence of being Phase III/IIIb or Phase II/III, which is a required criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of spinal versus general anaesthesia in high-risk non-muscle invasive bladder cancer: study protocol for a randomised controlled trial. PMID 41314851 · BMJ Open · 2025-Nov-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT. PMID 41314669 · RMD Open · 2025-Nov-28 The study is excluded because it is not in an oncology population (axial spondyloarthritis) and does not have a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term hormone therapy for perimenopausal and postmenopausal women. PMID 41307293 · Cochrane Database Syst Rev · 2025-Nov-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET): study protocol for a pragmatic randomised control trial of a patient-centred intervention to improve adherence to endocrine therapy in early breast cancer. PMID 41299751 · Trials · 2025-Nov-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
HPV self-sampling for cervical cancer screening among women living with HIV in Ghana: protocol for a hybrid type 1 effectiveness-implementation randomized controlled trial. PMID 41299750 · Trials · 2025-Nov-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Direct-to-Patient Digital Health Program for Lung Cancer Screening: A Randomized Clinical Trial. PMID 41114973 · JAMA · 2025-Nov-25 This is a randomized clinical trial on lung cancer screening, but it does not meet the core eligibility criteria: (1) It is not a Phase III/IIIb or Phase II/III trial of a therapeutic intervention for a malignant neoplasm; it is a Phase unspecified pragmatic trial of a digital health intervention for screening uptake. (2) The intervention is not a drug-containing regimen. (3) The primary efficacy endpoint is screening completion (a binary proportion), not a time-to-event outcome (e.g., OS, PFS, DFS) analyzed with Kaplan-Meier or hazard ratios.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
LIVERATION trial: a multicentre European randomised study on radiofrequency margin coagulation and its impact on oncological outcomes after liver surgery - study protocol. PMID 41290310 · BMJ Open · 2025-Nov-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Antibiotic stewardship in suspected neutropenic fever (ASTERIC trial): a multicentre, type 1 hybrid effectiveness-implementation, stepped-wedge, randomised controlled trial study protocol. PMID 41290295 · BMJ Open · 2025-Nov-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effectiveness and cost-effectiveness of risk-adapted colorectal cancer screening: a randomized controlled trial and modeling analysis. PMID 41287073 · Mil Med Res · 2025-Nov-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin. PMID 41286911 · Cost Eff Resour Alloc · 2025-Nov-24 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy analysis of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma. PMID 41286133 · Sci Rep · 2025-Nov-24 The record describes a randomized, controlled trial in oncology (hepatocellular carcinoma) with drug interventions (anlotinib, sintilimab) and time-to-event efficacy endpoints (PFS, OS). However, the trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III, which is a required criterion. Additionally, while time-to-event outcomes are reported, the abstract does not provide Kaplan-Meier curves or hazard ratios, which are key for digitization. Therefore, eligibility cannot be confirmed due to missing explicit phase evidence.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of Total Mesorectal Excision (TME) quality on 3-year overall survival in low rectal cancer based on the LASRE trial. PMID 41285886 · Sci Rep · 2025-Nov-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. PMID 41276263 · Cochrane Database Syst Rev · 2025-Nov-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial. PMID 41271680 · Nat Commun · 2025-Nov-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Oncological Outcomes of Patients Undergoing Radical Prostatectomy with Extended versus Indocyanine-Guided Lymphadenectomy: Midterm Follow-Up of PersonalymPCa Clinical Trial. PMID 41264563 · Urol Int · 2025-Nov-20 The trial is randomized and reports time-to-event efficacy (biochemical recurrence-free survival), but the intervention is a surgical technique (ICG-guided lymphadenectomy) not a drug-containing regimen. Therefore, it does not meet the drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Breast surgery for metastatic breast cancer. PMID 41263247 · Cochrane Database Syst Rev · 2025-Nov-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation. PMID 41043099 · J Clin Oncol · 2025-Nov-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of ligation sequence of the inferior mesenteric artery and vein on circulating tumour cells and survival in minimally invasive rectal cancer surgery: study protocol for a randomised controlled trial (ARVECTS study). PMID 41263842 · BMJ Open · 2025-Nov-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Preventive effects of combined live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus cereus tablets on radiation pneumonitis-associated with cyberknife treatment for pulmonary malignancies. PMID 41257942 · Ann Clin Microbiol Antimicrob · 2025-Nov-19 The record describes a randomized trial of a probiotic intervention to prevent radiation pneumonitis in lung cancer patients receiving CyberKnife therapy. While it meets criteria for oncology, human, randomized, time-to-event endpoint, and drug intervention, it does not meet the core requirement of being a definitive (Phase III/IIIb or Phase II/III) trial of a systemic anti-cancer drug regimen. The study is a supportive care/prevention trial, and the phase is not specified in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of a theory-driven, disclosure-based family support programme on fear of cancer recurrence for couples coping with breast cancer: protocol for a multi-centre randomised controlled trial. PMID 41257879 · Trials · 2025-Nov-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Chinese herbal medicine granules plus chemotherapy in patients with EGFR-mutated advanced lung adenocarcinoma post-progression on first-line EGFR-TKI: study protocol for a multicenter, double-blind, randomized controlled trial. PMID 41257744 · BMC Complement Med Ther · 2025-Nov-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial. PMID 41254229 · Commun Med (Lond) · 2025-Nov-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up). PMID 40581082 · Br J Dermatol · 2025-Nov-18 The record describes a Phase IIIb/IV randomized trial of upadacitinib for atopic dermatitis, which is a non-oncology condition. The primary efficacy endpoint is a categorical response (EASI 90) and does not involve time-to-event analysis (e.g., OS, PFS, KM curves).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Strategies to improve healthcare team communication structure and quality in resource-variable childhood cancer hospitals (TeamTalk): a study protocol. PMID 41250257 · Implement Sci Commun · 2025-Nov-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design. PMID 41249955 · BMC Cancer · 2025-Nov-17 The record is a clinical trial protocol for a randomized study in oncology patients, but it is not a report of formal results from a Phase III or Phase II/III trial. The primary endpoint is venous thromboembolism incidence, which is not a standard oncology efficacy endpoint (e.g., OS, PFS, DFS). No trial results, Kaplan-Meier data, or Hazard Ratios for oncology efficacy are provided.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial. PMID 40992225 · Eur J Cancer · 2025-Nov-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A qualitative study of Emotion and Symptom-focused Engagement (EASE): An integrated psychotherapeutic and early palliative care intervention for patients with acute leukemia. PMID 41240159 · Support Care Cancer · 2025-Nov-15 The record describes a qualitative study protocol for a psychotherapeutic intervention within a phase III RCT for acute leukemia. It is not a report of original formal results with a drug-containing intervention and a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Enhanced recovery after surgery protocol does not reduce the length of postoperative hospitalization after robot-assisted radical prostatectomy. Outcomes from the first randomized controlled trial: the (PROSTA-RAAC) study. PMID 41240114 · World J Urol · 2025-Nov-15 The study is a randomized controlled trial in oncology (prostate cancer), but it evaluates a non-drug intervention (Enhanced Recovery after Surgery protocol) and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary endpoint is length of hospitalization, a continuous outcome, and secondary endpoints include mobilization time and quality of life, not time-to-event measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy. PMID 40752653 · Int J Radiat Oncol Biol Phys · 2025-Nov-15 Long-term follow-up report of a randomized phase III trial in prostate cancer with a drug intervention (bicalutamide) and primary OS endpoint using Kaplan-Meier and HR. All eligibility criteria are explicitly met in the record.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 6 Figure · 6 Panel · risk visible
Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. PMID 40673336 · Int J Cancer · 2025-Nov-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prospective Phase 2 Clinical Trial of Carbon Ion Radiation Therapy Combined With Chemotherapy for Locally Advanced Pancreatic Carcinoma. PMID 40614787 · Int J Radiat Oncol Biol Phys · 2025-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Hypofractionated Preoperative Radiation Therapy for Extremity and Superficial Trunk Soft Tissue Sarcomas: Results of a Prospective, Phase 2 Trial. PMID 40389098 · Int J Radiat Oncol Biol Phys · 2025-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial. PMID 41239458 · Arthritis Res Ther · 2025-Nov-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -